Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elobixibat plus cholestyramine in NAFLD/NASH (Phase 2a, double-blind, randomized, placebo-controlled)
jRCT2080225028Phase 2Completed
- Sponsor
- Takaomi Kessoku
- Start
- Jan 2020
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) comparing Elobixibat + cholestyramine with Placebo (2 arms). Started Jan 2020; status: completed.
02
Drugs
elobixibatcholestyramine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2080225028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225028.